Update on the epidemiology and management of cryptococcal meningitis

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 6, 2012, Pages 783-789

  Desalermos, Athanasios ^a   Kourkoumpetis, Themistoklis K ^a   Mylonakis, Eleftherios ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amphotericin B; Cryptococcus gattii; Cryptococcus neoformans; Fluconazole; Flucytosine; Fungal infection; HIV infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; BONE MARROW TOXICITY; CHILL; CONFUSION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; CRYPTOCOCCUS GATTII; DELIRIUM; DIARRHEA; DIZZINESS; FEVER; FLUSHING; FUNGAL VIRULENCE; FUNGUS IDENTIFICATION; GRAFT RECIPIENT; HEADACHE; HEART ARREST; HEART VENTRICLE FIBRILLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LEUKOPENIA; MORTALITY; NAUSEA; NEPHROTOXICITY; RASH; REVIEW; SEDATION; SIDE EFFECT; THROMBOCYTOPENIA; VERTIGO; VOMITING;

ANTIFUNGAL AGENTS; CRYPTOCOCCUS; HUMANS; MENINGITIS, CRYPTOCOCCAL;

EID: 84858852151     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.658773     Document Type: Review

References (26)

1. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009;23:525-30. This study provides an estimation of the burden of cryptococcal meningitis worldwide and underlines the high morbidity and mortality in sub-Saharan Africa
2. Pukkila-Worley R, Mylonakis E. Epidemiology and management of cryptococcal meningitis: Developments and challenges. Expert Opin Pharmacother 2008;9:551-60
3. Liu OW, Chun CD, Chow ED, et al. Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 2008;135:174-88
4. De Jesus MD, Nicola AM, Chow SK, et al. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence 2010;1:500-8
5. Chow SK, Casadevall A. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine 2011;29:1891-8
6. Xue C, Liu T, Chen L, et al. Role of an expanded inositol transporter repertoire in Cryptococcus neoformans sexual reproduction and virulence. mBio 2010;1:e00084-10
7. Eisenman HC, Chow SK, Tse KK, et al. The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence 2011;2:329-36
8. Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog 2007;3:e101
9. Means TK, Mylonakis E, Tampakakis E, et al. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J Exp Med 2009;206:637-53. A basic research study analyzing the role of C. elegans receptors CED-1 and C03F11.3 and their mammalian homologues, scavenger receptors SCARF1 and CD36, in fungal immune response
10. Byrnes EJ III, Li W, Lewit Y, et al. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog 2010;6:e1000850. This study underlines the evolution of the highly virulent VGIIa and VGIIc genotypes in northwestern region of USA and analyses their pathogenicity and their ability to survive inside immune system cells
11. Hoang LM, Maguire JA, Doyle P, et al. Cryptococcus neoformans infections at Vancouver hospital and health sciences centre (1997 - 2002): Epidemiology, microbiology and histopathology. J Med Microbiol 2004;53:935-40
12. Byrnes EJ III, Marr KA. The outbreak of Cryptococcus gattii in western North America: Epidemiology and clinical issues. Curr Infect Dis Rep 2011;13:256-61
13. Centers for Disease Control and Prevention. Emergence of Cryptococcus gattii - Pacific Northwest, 2004 - 2010. MMWR Morb Mortal Wkly Rep 2010;59:865-8
14. Fraser JA, Giles SS, Wenink EC, et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005;437:1360-4. A study that reports on the origin and the virulence of the C. gattii isolates from the Vancouver Island outbreak. The results showed that the isolates are higly virulent and the hypothesis advanced that they generated from the cross of two alpha mating strains
15. Ma H, Hagen F, Stekel DJ, et al. The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc Natl Acad Sci USA 2009;106:12980-5. This study demonstrates the enhanced ability of C. gattii genotypes from the Vancouver Island outbreak to replicate inside the macrophages and links this characteristic with virulence
16. Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 2011;53:321-5
17. Shelburne SA III, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:1049-52
18. Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: A prospective multicenter study. Clin Infect Dis 2009;49:931-4
19. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009;23:701-6
20. Wijewardana I, Jarvis JN, Meintjes G, et al. Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. J Infect 2011;63:484-6
21. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010;50:291-322
22. Sun HY, Alexander BD, Lortholary O, et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009;49:1721-8. A study of 75 patients with of CNS cryptococcosis after a solid organ transplantation found that lipid formulations of amphotericin B are associated with better outcomes than amphotericin B deoxycholate
23. Byrnes EJ III, Bartlett KH, Perfect JR, Heitman J. Cryptococcus gattii: An emerging fungal pathogen infecting humans and animals. Microbes Infect 2011;13:895-907
24. Lee YC, Wang JT, Sun HY, Chen YC. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect 2011;44:338-45
25. Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2011; 54(1):121-8
26. Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: A randomized trial in Malawi. Clin Infect Dis 2010;50:338-44. A study of 41 HIV-seropositive patients that examined the efficacy of fluconazole monotherapy versus combination therapy with flucytosine. The results showed the superiority of the combination therapy.